Year: 2025
Type: article
Abstract: Translational oncology biomarkers bridge the gap between tumour biology discovery and clinical application, guidingdiagnosis, prognosis, treatment selection, and response monitoring across the expanding armamentarium of cancertherapies. The past decade has witnessed explosive growth in candidate biomarkers -- from traditionalimmunohistochemistry markers through molecular alterations, gene expression signatures, circulating tumour DNAkinetics, microbiome composition, and multi-modal imaging-pathology-molecular composites -- but the translation frombiomarker discovery to validated clinical utility has been slower and more variable than the pace of discovery mightsuggest. Understanding which translational pathways most efficiently convert biomarker candidates into clinically usefultools is essential for prioritising limited biomarker qualification resources. We evaluated five translational oncologybiomarker pathway frameworks applied to 186 biomarker programmes across 22 European academic cancer centresand industry sites in Paris, Rome, Stockholm, Barcelona, and Heidelberg between 2012 and 2024. Frameworks rangedfrom single-laboratory discovery through fully integrated consortium development with companion diagnosticco-development and regulatory qualification. Performance was benchmarked using our Translational OncologyBiomarker Effectiveness Score (TOBES), integrating analytical validation rigour, clinical validation breadth, clinical utilitydemonstration, regulatory qualification achievement, and implementation reach. The fully integrated consortiumframework achieved the highest TOBES (0.918), reducing time from biomarker discovery to companion diagnosticapproval from 7.8 years to 3.4 years and achieving clinical implementation in 78.4% of European oncology centresversus 32.4% for single-laboratory development. ctDNA-based minimal residual disease biomarkers and multi-genetumour profiling panels exemplified successful integrated translation
Authors: Pierre Lindberg, Marco Petrov, Lea Garcia
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7203663514
